1.99
Precedente Chiudi:
$2.08
Aprire:
$2.08
Volume 24 ore:
51,156
Relative Volume:
0.26
Capitalizzazione di mercato:
$6.85M
Reddito:
$895.50K
Utile/perdita netta:
$-26.30M
Rapporto P/E:
-1.2134
EPS:
-1.64
Flusso di cassa netto:
$-23.84M
1 W Prestazione:
+8.15%
1M Prestazione:
+39.16%
6M Prestazione:
-55.28%
1 anno Prestazione:
-86.18%
Mainz Biomed N V Stock (MYNZ) Company Profile
Nome
Mainz Biomed N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MYNZ con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MYNZ
Mainz Biomed N V
|
1.99 | 7.59M | 895.50K | -26.30M | -23.84M | -1.64 |
![]()
TMO
Thermo Fisher Scientific Inc
|
475.03 | 176.18B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
202.81 | 141.70B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
549.97 | 43.48B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
IQV
Iqvia Holdings Inc
|
200.82 | 33.02B | 15.50B | 1.33B | 2.16B | 7.34 |
![]()
A
Agilent Technologies Inc
|
120.35 | 33.01B | 6.63B | 1.17B | 1.19B | 4.05 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-14 | Iniziato | Maxim Group | Buy |
2024-11-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-11-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2022-06-21 | Iniziato | H.C. Wainwright | Buy |
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Does Mainz Biomed N.V. stock pay reliable dividendsFree Stock Market Return Analysis - jammulinksnews.com
What drives Mainz Biomed N.V. stock priceHigh-velocity gains - Autocar Professional
Mainz Biomed, CARE announce collaboration agreement - TipRanks
Mainz Biomed Partners with CARE Diagnostica to Enhance Colorectal Cancer Screening in Germany - Nasdaq
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies - GlobeNewswire
Mainz Biomed Expands Early Cancer Detection Program to 19 German Health Insurers Through CARE Partnership - Stock Titan
When the Price of (MYNZ) Talks, People Listen - news.stocktradersdaily.com
What analysts say about Mainz Biomed N.V. stockConsistently profitable trades - jammulinksnews.com
Is Mainz Biomed N.V. a good long term investmentRapid growth trajectories - jammulinksnews.com
Mainz Biomed N.V. Stock Analysis and ForecastBreakthrough profits - Autocar Professional
Why Mainz Biomed N.V. stock attracts strong analyst attentionFree Long-Term Wealth Growth Plan - beatles.ru
Mainz Biomed (NASDAQ:MYNZ) Trading Up 7% – Here’s Why - Defense World
Mainz Biomed Half Year 2025 Update: Accelerating FDA - GlobeNewswire
What makes Mainz Biomed N.V. stock price move sharplyFree Stock Market Expert Consultation - Newser
ARBI(arbipad) News and UpdatesProtected Capital Trading Plan - Newser
How Mainz Biomed N.V. stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
Mainz Biomed reviews accomplishments for first half of 2025 - TipRanks
Mainz Biomed N.V. Announces Key Achievements and Corporate Update for First Half of 2025 - Nasdaq
Mainz Biomed's Dual Breakthrough: FDA Trial Progress and Revolutionary 95% Accurate Pancreatic Cancer Detection - Stock Titan
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - 富途牛牛
Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer Project | MYNZ Stock News - GuruFocus
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - FinancialContent
Mainz Biomed (MYNZ) to Release Quarterly Earnings on Tuesday - Defense World
Where are the Opportunities in (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Down 1.9% – Here’s What Happened - Defense World
(MYNZ) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Ca - GuruFocus
Mainz Biomed Initiates Feasibility Study Of PancAlert Blood Test For Pancreatic Cancer Detection - Nasdaq
Mainz Biomed Initiates Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project - MarketScreener
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Cancer Detection | MYNZ Stock News - GuruFocus
Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project - Nasdaq
Mainz initiates feasibility study of biomarker panel in PancAlert project - TipRanks
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - The Manila Times
Mainz Biomed N V Azioni (MYNZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):